Immatics NV
NASDAQ:IMTX

Watchlist Manager
Immatics NV Logo
Immatics NV
NASDAQ:IMTX
Watchlist
Price: 7.03 USD 2.63%
Market Cap: 839.1m USD
Have any thoughts about
Immatics NV?
Write Note

EV/EBIT
Enterprise Value to EBIT

-4.8
Current
-7.4
Median
4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-4.8
=
Enterprise Value
333.3m USD
/
EBIT
-67.2m EUR
All Countries
Close
Market Cap EV/EBIT
DE
Immatics NV
NASDAQ:IMTX
831.3m USD -4.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 971.5
US
Abbvie Inc
NYSE:ABBV
311.8B USD 23.5
US
Amgen Inc
NASDAQ:AMGN
140.7B USD 30.2
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD 22.2
US
Epizyme Inc
F:EPE
94.1B EUR -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD 16.9
US
Seagen Inc
F:SGT
39.3B EUR -53
NL
argenx SE
XBRU:ARGX
36B EUR -79.8
EBIT Growth EV/EBIT to Growth
DE
Immatics NV
NASDAQ:IMTX
Average EV/EBIT: 21.3
Negative Multiple: -4.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.5
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.2
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.8 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-4.1
2-Years Forward
EV/EBIT
-2
3-Years Forward
EV/EBIT
-1.7

See Also

Discover More